Establishing Global Markets & Breaking Into Emerging Markets

8:15 - Continental Breakfast And Conference Registration Networking Breakfast And Conference Registration Registration Sponsored By:

9: 00 - Chairpersons Opening Address Ira Weiss, Board of Directors-Corporate Secretary, BioDtech, Inc. No session description available. Ira Weiss Board of Directors-Corporate Secretary, BioDtech, Inc. As a Founder and executive Ira Weiss has primary responsibility for the financial operation including the contract negotiations, intellectual property transfer, grant development, audit requirements and general operations of the company. He has worked extensively with universities, non-profit foundations and research facilities, pharmaceutical companies and executives at both management and board [read more]

9:15 - The Need For FDA Approved Pediatric Medications Peter Joiner, President & CEO, Madeira Therapeutics No session description available. Peter Joiner President & CEO, Madeira Therapeutics Peter R. Joiner, CEO and President Madeira Therapeutics, has a 30-year history in sales, sales management, and marketing for pharmaceutical companies. These have included executive-level sales force management, pharmaceutical company strategic business planning/business analysis, and large customer account management. He has launched over 15 major pharmaceutical products and established significan [read more]

9:55 - Leveraging Your Assets To Expand Your Pipeline - Case Study: Emergent BioSolutions Jacob Licht, Director of Corporate Development, Emergent BioSolutions No session description available. Jacob Licht Director of Corporate Development, Emergent BioSolutions As Director of Corporate Development at Emergent BioSolutions in Rockville, MD, Jacob’s responsibilities include overseeing strategic planning; identifying and evaluating licensing and acquisition opportunities; and negotiating transactions. Since joining Emergent Jacob has identified and negotiated several transactions supporting the company’s biodefense and commercial efforts. Prior to joining E [read more]

10:35 - Refreshment Break And Networking Opportunity Refreshment Break And Networking Opportunity

11:10 - PANEL: Building In An Exit Strategy: Making Your Biotech Attractive To Venture Capital Francois Martelet, President & CEO, Avax Technologies Angie You, Chief Business Officer, Synosia Therapeutics Stephen R. Brady, Executive Director, Corporate Development, Proteolix Inc John Hollway, Senior VP, Corporate Development, Achaogen As one VC recently stated, “the venture capital system is broken”, as the potential for inflating the value of a start-up is eliminated by the current state of the IPO market. Now, VCs must turn to partnering as their main option to render the profits that they have promised their investors. Join this panel of venture backed biotechs and venture capital firms as they discuss how the venture strategy will be remodeled to align itself with today’s risk-averse philosophy. Coping with acquisitions structured much like a licensing agreement, with small upfront payments followed by several subsequent milestone payments Re-aligning the VC strategy to nurture the development of several assets Supporting the “technology platform” model to ensure that the company has several assets eligible for funding Francois Martelet President & CEO, Avax Technologies Francois Martelet is a Senior Executive in the Pharmaceutical & Biotech Industry where he brings about 20 years’ of medical, marketing, sales and business unit management experience. He is currently is now providing consulting services to Cegedim Dentrite, the world's leading CRM provider for the healthcare sector and developer of exclusive databases and high value-added software solutions.Fra [read more] Angie You Chief Business Officer, Synosia Therapeutics Prior to joining Synosia, Angie was CBO at Ren Pharmaceuticals where she oversaw operations, finance and corporate development. Angie also spent time as a Vice President at Venrock Associates where she worked primarily on new company building and corporate development activities for portfolio companies. During her tenure at Venrock, she served as the interim VP of Business Development for Anacor P [read more] Stephen R. Brady Executive Director, Corporate Development, Proteolix Inc Steve is the Executive Director, Corporate Development of Proteolix, Inc., a privately-held biopharmaceutical company focused on treating certain cancers and immunological conditions by discovering and developing products that inhibit the proteasome. From 2001 until 2007, Steve was with Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capac [read more] John Hollway Senior VP, Corporate Development, Achaogen Mr. Hollway manages Achaogen's financial and strategic operations, and is responsible for its non-dilutive financing efforts. He was most recently the Vice President of Operations, Strategy & Corporate Development, and Chief Privacy Officer for Acurian, Inc., a clinical services company. There he built the company's clinical data services and had responsibility for the overall management of cl [read more]

11:50 - Rome Couldn’t Be Built In A Day And Nor Can A New Therapeutic Business…The Latter Takes About 6 Weeks Martin Reeves, VP Business Development, Cephalon Inc. Churchill said “A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty”. During a time of economic chaos and in a matter of 6 weeks, Cephalon executed a series of transactions that transformed it into a significant player in the biologics space adding to its existing core of small molecule products and opportunities. Martin will discuss how Cephalon made this transition almost overnight, capitalizing on a unique set of internal and external circumstances and as a result setting a new course for Cephalon. Martin Reeves VP Business Development, Cephalon Inc. Martin Reeves has almost 30 years of experience in the pharmaceutical industry in both Europe and in the U.S., in roles as varied as research, project management, alliance management, strategic planning, business development and general operations. He joined Cephalon as the head of Project Management in 1997 and has helped coordinate numerous activities important to the company’s success. Currentl [read more]

12:30 - Lunch And End Of BioNetwork 2009 Lunch And End Of BioNetwork 2009